Drug
M5049 Low Dose
M5049 Low Dose: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| M5049 low dose NCT05540327 | Phase 2 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow M5049 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.